Rare diseases
Investigational molecules
Locations
A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
SpainStudy of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
SpainStudy of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy
SpainStudy of denikitug alone or with drug combination in adults with HER2‑negative metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma
SpainSafety and early efficacy of TranspoCART19 CAR‑T CD19 therapy in patients with refractory lupus nephritis (Phase I‑IIa)
SpainVenetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia
SpainPhase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors
SpainStudy of MK-1045 plus rituximab in patients with newly diagnosed follicular lymphoma
SpainPhase Ib/II Study of Bexmarilimab Plus Doxorubicin in Adults with Metastatic Soft Tissue Sarcoma
SpainSafety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
SpainPhase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo
SpainStudy of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients
SpainTell us about your condition – we search every trial in Europe and connect you with the right site.
